Author： Arnold Lesley M McElroy Susan L Keck Paul E
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.6, 2001-06, pp. : 1033-1042
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a Medline® search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.
Related content
By Albers Lawrence James Musenga Alessandro Raggi Maria Augusta
Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. :
Access to resources
Recommend
By Orjales A. Mosquera R. Toledo A. Pumar C. Labeaga L. Innerarity A.
European Journal of Medicinal Chemistry, Vol. 37, Iss. 9, 2002-09 ,pp. :
Olanzapine: an atypical antipsychotic for schizophrenia
Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 2, 2000-01 ,pp. :
Atypical Antipsychotic Metabolism and Excretion
Current Drug Metabolism, Vol. 11, Iss. 6, 2010-01 ,pp. :